{'52WeekChange': 3.838759,
 'SandP52WeekChange': None,
 'address1': '33 Arch Street',
 'address2': 'Suite 3110',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 88.75,
 'askSize': 1000,
 'averageDailyVolume10Day': 123150,
 'averageVolume': 246077,
 'averageVolume10days': 123150,
 'beta': None,
 'beta3Year': None,
 'bid': 80,
 'bidSize': 800,
 'bookValue': 6.942,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 94.46,
 'dayLow': 87.54,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -48.04,
 'enterpriseToRevenue': None,
 'enterpriseValue': 2105016320,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 99.510574,
 'fiftyTwoWeekHigh': 152,
 'fiftyTwoWeekLow': 11.24,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 16079953,
 'forwardEps': -2.8,
 'forwardPE': -31.642857,
 'fromCurrency': None,
 'fullTimeEmployees': 19,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.21173,
 'heldPercentInstitutions': 0.6353,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/karunatx.com',
 'longBusinessSummary': 'Karuna Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, primarily focuses on '
                        'developing novel therapies to address disabling '
                        'neuropsychiatric disorders and pain. Its lead product '
                        'candidate is KarXT, an oral modulator that has '
                        'completed Phase II clinical trial for the treatment '
                        'of acute psychosis in patients with schizophrenia; '
                        'and in Phase Ib clinical trial for the treatment of '
                        'central nervous system disorders, such as negative '
                        'and cognitive symptoms of schizophrenia and '
                        "psychosis, Alzheimer's, and pain, as well as for the "
                        'treatment of dementia-related psychosis. The company '
                        'also focuses on developing other muscarinic-targeted '
                        'drug candidates. Karuna Therapeutics, Inc. has a '
                        'license agreement with Eli Lilly and Company; patent '
                        'license agreement with PureTech Health LLC; and drug '
                        'discovery partnership with Charles River '
                        'Laboratories. The company was formerly known as '
                        'Karuna Pharmaceuticals, Inc. and changed its name to '
                        'Karuna Therapeutics, Inc. in March 2019. Karuna '
                        'Therapeutics, Inc. was founded in 2009 and is '
                        'headquartered in Boston, Massachusetts.',
 'longName': 'Karuna Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 2315126784,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_134115017',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -40610000,
 'nextFiscalYearEnd': 1640908800,
 'open': 94.46,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857-449-2244',
 'previousClose': 95.13,
 'priceHint': 2,
 'priceToBook': 12.762893,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 94.46,
 'regularMarketDayLow': 87.54,
 'regularMarketOpen': 94.46,
 'regularMarketPreviousClose': 95.13,
 'regularMarketPrice': 94.46,
 'regularMarketVolume': 231721,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 26130100,
 'sharesPercentSharesOut': 0.0723,
 'sharesShort': 1888366,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1017983,
 'shortName': 'Karuna Therapeutics, Inc.',
 'shortPercentOfFloat': 0.16450001,
 'shortRatio': 6.09,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'KRTX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.901,
 'twoHundredDayAverage': 87.92446,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '94ef712e-8642-32d7-afd7-4c98c2966391',
 'volume': 231721,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.karunatx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02110'}